Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253084 · ClinicalTrials.gov registry record · Phase 2
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT00253084: Completed Phase 2 study of Parkinson's Disease, sponsored by Impax Laboratories.
NCT00253084 is a Phase 2 study of Parkinson's Disease that has completed, run by Impax Laboratories. The registered enrollment target is 12 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00253084, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinson's disease.
Conditions Studied
Interventions
- DRUG IPX054 200 mg
- DRUG CD-LD IR
- DRUG IPX054 Placebo
- DRUG CD-LD IR Placebo
Study Locations (2)
Illinois
- Site 1 - Chicago
South Carolina
- Site 2 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00253084 record still lists
NCT00253084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 4 interventions - of which IPX054 200 mg is the first listed.
NCT00253084 reports a single indexed study location in Illinois, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00253084 about?
NCT00253084 is a clinical study titled "Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease". The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinson's disease.
What is the current status of trial NCT00253084?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-11. Estimated completion is 2007-12.
What conditions does trial NCT00253084 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00253084?
The interventions under investigation include: IPX054 200 mg (DRUG), CD-LD IR (DRUG), IPX054 Placebo (DRUG), CD-LD IR Placebo (DRUG).
Who is sponsoring clinical trial NCT00253084?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00253084 being conducted?
This trial has 2 study locations across Illinois, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00253084's enrollment target sits among peer trials
12 143rd of 158 higher than 15 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia